Kristen A. Marrone
Oncology
300 Mason Lord Drive, Kimmel Cancer Center
Kimmel Cancer Center
Baltimore, MD 21224
Kimmel Cancer Center
Baltimore, MD 21224
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 17, 2026
Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 25, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 17, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 03, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 03, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 19, 2026
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.
Journal: Cancer research communications
Published: September 15, 2025
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 17, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2025
Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: March 21, 2025
Last Updated: 09/26/2026